The team plans to test RI-AG03 in rodents before launching clinical trials. However, prior promising tau-based therapies have failed in clinical trials.

Research on RI-AG03 was funded by charity the Alzheimer's Society UK. Its associate director of research and innovation Dr Richard Oakley welcomed the results.

Testing RI-AG03. To test its effectiveness in cells within a living organism, researchers at the University of Southampton then gave the drug to fruit flies that had pathogenic Tau.

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing promise in early trials and lab tests. How the new drug works in the ...

They found that RI-AG03 penetrated the cells and reduced the aggregation of tau proteins, too. "What is new here, is that the authors have invented a molecule that binds to both tau hotspot regions.

Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease. The drug, a peptide inhibitor called RI-AG03, successfully ...

RI-AG03 targets main promoters of tau protein aggregation at once Oct. 4, 2024 These hotspots, essential for aggregation, include (306)VQIVYK(311) and (275)VQIINK(280) aggregation-promoting hotspots, ...

A team of international researchers has found a promising new drug candidate for the treatment of Alzheimer’s disease. The scientists say they have developed a peptide inhibitor called RI-AG03 ...

Study found that the medication, called RI-AG03, was effective at preventing the buildup of Tau proteins. Nina Massey. Thursday 03 October 2024 15:59 BST. open image in gallery.

Testing RI-AG03. To test its effectiveness in cells within a living organism, researchers at the University of Southampton then gave the drug to fruit flies that had pathogenic Tau.

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized hotspots which are different from tau microtubules. These hotspots, essential ...